Document is current
Any future updates will be listed below
-
Authors
Grinshpun, Albert https://orcid.org/0000-0002-3351-5719
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
Burstein, Harold J.
Jeselsohn, Rinath https://orcid.org/0000-0001-7996-7529
Mayer, Erica L. https://orcid.org/0000-0001-5430-8957
-
Funding
Funding for this research was provided by:
AG is funded by the Conquer Cancer - Israel Cancer Research Fund Career Development Award.
- License Information
-
More Information
Article History
Received: 25 August 2022
Accepted: 3 March 2023
First Online: 22 March 2023
Competing interests
: S.M.T. reports consulting or advisory roles for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Chugai Pharmaceuticals, Zetagen, Myovant, Umoja Biopharma, Menarini/Stemline, Aadi Bio, and Bayer; and institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Sanofi, and Seattle Genetics. R.J. reports research funding from Pfizer and Lilly and an advisory board role for GE Healthcare. E.L.M. reports consulting roles for Novartis, Gilead, AstraZeneca, and Lilly. The remaining authors declare no competing interests.
